SynthesisDaru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences2025
Efficacy of dostarlimab in recurrent or advanced mismatch Repair-Deficient endometrial Cancer as a Single-Agent therapy: A systematic review and Meta-Analysis.
Synthesis in Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Precision Therapeutics in Pancreatic Cancer: Emerging Targeted, Immune, and Antibody-Drug Conjugate Strategies Exemplified by Adagrasib, Dostarlimab, and Trastuzumab Deruxtecan.Journal of clinical medicine · 2026Review
- Subcutaneous immunotherapy as a catalyst for decentralized, oncologist-led cancer care: a mixed-methods analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe effectiveness of PD-1 inhibitors for treating endometrial cancer (EC) remains a topic of debate. Guidelines lack consistency regarding the preferred treatments for advanced cases, as well as for patients experiencing metastasis or recurrence. Thus, our goal was to assess the efficacy of Dostarlimab, a PD-1 inhibitor, in EC by incorporating data from clinical trials to create a more comprehensive database.
methodsWe conducted a thorough and systematic search of the Scopus, Medline, Embase, and Web of Science databases, identifying all eligible studies on Dostarlimab's efficacy in endometrial cancer.
resultsOur data demonstrated that the hazard ratio of OS in the pooled proportion of participants was 43%. The hazard ratio of PFS in the pooled proportion of EC patients was 0.39 (95% CI: 0.31-0.49). The overall analysis generated a probability of remaining in response of 72.71% (95% CI: 60.94-84.49%). In addition, pooling the results from both subgroups of EC patients, including proficient mismatch repair (pMMR) and deficient mismatch repair (dMMR), yielded an ORR of 33.93% (95% CI: 21.49-46.37%) and a DCR of 51.73% (95% CI: 37.0-66.42%). Overall, the deficient mismatch repair group compared to the proficient mismatch repair group showed better outcomes. Finally, the dMMR subgroup showed a median PFS of 7.86 months (95% CI: 4.46-11.26).
conclusionDostarlimab demonstrated limited efficacy in patients with pMMR EC, but it represented better outcomes in those with dMMR EC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.